GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

atumelnant

Company
Crinetics Pharmaceuticals Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for atumelnant and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06712823

    An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

    Not yet reported Crinetics Pharmaceuticals Inc. 200 participants Est. completion 2029-08 13 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
    View official trial listing →
  • Recruiting NCT NCT07144163

    A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

    Not yet reported Crinetics Pharmaceuticals Inc. 150 participants Est. completion 2027-05 68 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
    View official trial listing →
  • Recruiting NCT NCT07159841

    A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

    Not yet reported, Not yet reported Crinetics Pharmaceuticals Inc. 153 participants Est. completion 2030-03 48 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
    View official trial listing →
  • Active, not recruiting NCT NCT05804669

    A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

    Not yet reported, Not yet reported Crinetics Pharmaceuticals Inc. 19 participants Est. completion 2026-10 1 site Stand-alone
    Other conditions: Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
    View official trial listing →
  • Completed NCT NCT05907291

    Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

    Not yet reported Crinetics Pharmaceuticals Inc. 38 participants Est. completion 2025-08-22 27 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT07221084

    A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

    Not yet reported Crinetics Pharmaceuticals Inc. 21 participants Est. completion 2026-02-27 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT07570082

    Drug-Drug Interaction Study of Atumelnant in Healthy Participants

    Not yet reported Crinetics Pharmaceuticals Inc. 46 participants Est. completion 2026-07-30 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: atumelnant, atumelnant (CRN04894)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.